Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

SIM0270 is an oral, selective estrogen receptor degrader (SERD)

palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6

Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)